Wei Tang, Ph.D.
Dr. Wei Tang is interested in molecular epidemiology studies of prostate and breast cancer with a focus on health disparities. He utilizes translational research and systems biology approaches to identify exposures and related pathways that drive tumor development and progression in these cancers. His research includes the large-scale analysis of gene expression and epigenetic modification, the evaluation of the tumor metabolome and proteome, and the discovery of biomarkers via WES, VirScan and genome-wide association studies (GWAS) for diseases.
1) bioinformatics, 2) data science, 3) cancer genetics and genomics, 4) translational research, 5) molecular epidemiology
We described the proteome in breast cancer and its relationship to the transcriptome and breast cancer outcomes (Tang, et al., Genome Med 2018), and also discovered the accumulation of liver-and microbiome-derived bile acids in breast tumors and its functional relationship to a very distinct tumor biology (Tang, et al., Clin Cancer Res 2019).
We studied the epidemiology and function of a novel human interferon gene in prostate cancer. We investigated the relationship between a germline variation and the occurence of an interferon signature that we discovered in prostate tumors of African-American men (Tang, et al., Clin Cancer Res 2018).
We reported an epidemiology study that aspirin use significantly reduces prostate cancer mortality among African-American patients in the NCI-Maryland Prostate Cancer Case-Control Study and a large prospective population-based study (SCCS) (Tang, et al., CEBP 2020).
We have expertise in data science and build bioinformatic pipelines that parse datasets from gene microarrays, RNA-seq, Methyl-seq, Exome-seq, ChIP-seq, Virome-seq, proteomics, metabolomics and GWAS to support research within the Molecular Epidemiology Section and the Laboratory of Human Carcinogenesis. Our analysis tools are being used by investigators to examine Omics data, allowing their integration and a more sophisticated analysis in a collaborative research environment (Liu*, Tang*, et al., Cell 2020).
Selected Key Publications
IFNL4-ΔG Allele Is Associated with an Interferon Signature in Tumors and Survival of African-American Men with Prostate Cancer .Clin Cancer Res. 24(21): 5471-5481, 2018. [ Journal Article ]
- J Clin Invest. 128(1): 323-340, 2018. [ Journal Article ]
Integrated proteotranscriptomics of breast cancer reveals globally increased protein-mRNA concordance associated with subtypes and survival.Genome Med. 10(1): 94, 2018. [ Journal Article ]
Liver- and Microbiome-derived Bile Acids Accumulate in Human Breast Tumors and Inhibit Growth and Improve Patient Survival.Clin Cancer Res. 25(19): 5972-5983, 2019. [ Journal Article ]
- Cell. 2020. [ Journal Article ]
Dr. Tang obtained his Ph.D. degree in Biochemistry and Molecular Biology in Human Genetics from Shanghai Jiao Tong University, Shanghai, China (2008). As a Visiting Fellow he trained at the Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics (DCEG), NCI (2009-13) and was promoted to Research Fellow in 2013. He joined the Molecular Epidemiology Section of the Laboratory of Human Carcinogenesis as a Staff Scientist in 2014 and promoted to Associate Scientist in 2020. Dr. Tang has been steadily productive with numerous research papers and he has received many awards, including the Fellows Award for Research Excellence (FARE), the CCR Staff Scientist/Staff Clinician Research Award (SS/SC-RA), the CCR Federal Technology Transfer Award, the NCI Director's Innovation Award for Career Development, the NIH Method to Extend Research in Time (MERIT) Group Award, the DCEG Intramural Research Award, and others. He is an active member of the Staff Scientist and Staff Clinician (SSSC) community at CCR.